Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
暂无分享,去创建一个
M. Cooperberg | P. Carroll | J. Broering | H. Akaza | Kazuto Ito | M. Namiki | S. Hinotsu
[1] A. D'Amico,et al. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer , 2008, Cancer.
[2] Pierre I Karakiewicz,et al. An updated catalog of prostate cancer predictive tools , 2008, Cancer.
[3] N. Kinukawa,et al. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer , 2008, The Journal of urology.
[4] A. Partin,et al. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. , 2008, Urology.
[5] Dirk F Moore,et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. , 2008, JAMA.
[6] E. Klein,et al. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population , 2008, Cancer.
[7] H. Akaza. Current status and prospects of androgen depletion therapy for prostate cancer. , 2008, Best practice & research. Clinical endocrinology & metabolism.
[8] T. Wilt,et al. Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer , 2008, Annals of Internal Medicine.
[9] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[10] I. Tannock,et al. A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.
[11] A. D'Amico,et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. , 2007, Journal of the National Cancer Institute.
[12] H. Akaza,et al. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. , 2007, Japanese journal of clinical oncology.
[13] A. D'Amico,et al. Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.
[14] N. Keating,et al. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Y. Homma,et al. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10‐year follow‐up , 2006, BJU international.
[16] M. Kattan,et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.
[17] Terukazu Nakamura,et al. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate‐specific antigen testing , 2005, International journal of urology : official journal of the Japanese Urological Association.
[18] M. Cooperberg,et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. , 2005, The Journal of urology.
[19] James A Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[20] J. Goodwin,et al. Increasing use of gonadotropin‐releasing hormone agonists for the treatment of localized prostate carcinoma , 2005, Cancer.
[21] C. Pashos,et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy , 2004, Cancer.
[22] H. Akaza,et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. , 2004, Japanese journal of clinical oncology.
[23] M. Cooperberg,et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. , 2004, The Journal of urology.
[24] M. Cooperberg,et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). , 2003, The Journal of urology.
[25] M. Cooperberg,et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. , 2003, Journal of the National Cancer Institute.
[26] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .
[28] A. Renshaw,et al. Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .
[29] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[30] J. Ferlay,et al. Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.
[31] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[32] M. Garnick. Current status of endocrine therapy for prostate cancer. , 1987, Oncology.